Takeda Loses Pre-Trial Skirmish In U.S. Court Over Missing Actos Files
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical lost a procedural battle in a U.S. federal court when the judge said she would allow testimony alleging the drug maker destroyed potentially damaging files related to its Actos (piaglitazone) diabetes drug.